ImmuCell develops, manufactures and markets animal health biologics for calf health and cattle productivity. Its primary product line, First Defense, uses colostrum-derived, orally delivered antibodies to provide Immediate Immunity against principal viral and bacterial causes of scours in newborn dairy and beef calves.
Company announcements commonly address preliminary product sales, unaudited financial results, manufacturing efficiency, commercial expansion, and the strategic focus on the First Defense franchise. Other recurring developments include board composition, committee structure, senior employment agreements, and updates tied to the paused investment in Re-Tain and related asset use.
ImmuCell provided an update on the regulatory status of its product development initiative for Re-Tain®. The company received a Technical Section Incomplete Letter from the FDA for its third submission of the CMC Technical Section, important for its NADA. ImmuCell has prepared a fourth submission but must clear inspectional observations at its facilities before submitting. The FDA confirmed acceptable inspectional status for ImmuCell, and its contract manufacturer expects to respond to inspectional observations by end of June 2024. The company anticipates a Non-Administrative NADA submission, possibly subject to a shorter review period, aiming for FDA approval and a controlled launch strategy between Q2 2025 and Q1 2026.
ImmuCell (Nasdaq: ICCC) has announced that its 2024 Annual Meeting of Stockholders will be held virtually on June 13, 2024, at 9:30 AM ET. The meeting will be conducted via telephone conference call and live audio webcast, not in person. Stockholders of record as of April 15, 2024, can participate by dialing specific toll-free numbers or accessing the webcast. Participation in the Q&A session post-meeting will be to the telephone call. A replay will be available until June 19, 2024. Stockholders are encouraged to vote in advance via proxy. More information is available on the company's website and SEC filings.
ImmuCell (Nasdaq: ICCC) reported a significant 111% year-over-year increase in product sales for Q1 2024, totaling $7.3 million. This marks the highest quarterly sales in the company's history. The trailing twelve-month sales also rose by 33%, reaching $21.3 million. Gross margin improved to 32%, up from 9% in Q1 2023. Despite these gains, the company reported a net loss of $438,000, a substantial improvement from the $2.3 million loss in the same period last year. EBITDA turned positive at $377,000 from a negative $1.6 million in Q1 2023. A backlog of $9.1 million in orders remains. However, cash reserves decreased slightly to $960,000. The FDA has delayed the approval of ImmuCell's Re-Tain® product due to pending inspectional observations at their contract manufacturer.
ImmuCell (Nasdaq: ICCC) will announce unaudited financial results for the quarter ended March 31, 2024 on May 14, 2024. The conference call to review the results is scheduled for May 15, 2024. Interested parties can access the call by dialing (844) 855-9502 (toll free) or (412) 317-5499 (international) at 9:00 AM ET. The Company expects no change to the preliminary sales results disclosed on April 9, 2024. Investors can review the updated Corporate Presentation slide deck on the Company's website.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
ImmuCell (ICCC) expects to release unaudited financial results for the quarter ended September 30, 2023, after the November 13 market close.
The company expects to file its quarterly Form 10-Q that evening. It anticipates no change to the preliminary third-quarter sales results disclosed on October 5. A call to review the financial results is scheduled for November 14 at 9:00 a.m. ET.